体细胞重编程为多能干细胞的研究进展

体细胞通过重编程转变成其他类型的细胞,在再生医学方面具有重要的应用前景。细胞重编程的方法主要有体细胞核移植、细胞融合、细胞提取物诱导、限定因子诱导等,这些方法可以不同程度地改变细胞命运。最近,限定因子诱导的多能干细胞（induced pluripotent stem cell。iPS）为重编程提供了一种崭新的方法,不仅可以避免伦理争议,还提供了一种更为便利的技术,为再生医学开辟了新的天地;同时,iPS技术为研究基因表达调控、蛋白质互作、机体生长发育等提供了一个非常重要的研究手段。本文主要论述了体细胞重编程的方法及iPS细胞的进展、面临的问题和应用前景。     

猪诱导性多能干细胞技术的研究进展及应用前景

猪作为实验材料,具有由于来源方便、基因序列与人类的相近及其在畜牧业中的重要地位等优势,成为国内外研究的热点,但是猪的胚胎干细胞(Embryonic stem cells,ESC)建系方面的研究进展缓慢。诱导性多能干细胞(induced pluripotent stem cells,iPSC)技术的诞生,开创了体细胞重编程的全新方法。猪iPSC体系的建立将为家畜ESC体系的建立奠定基础,同时也对提高猪转基因克隆的效率,高效育种和保种,乃至生物医学领域均产生深远的影响。文章综述了iPSC技术的主要进展,重点阐述了猪iPSC技术的现状及其在生物医学和畜牧业中的应用前景,以期为从事该领域研究的科研人员提供参考。     

诱导性多潜能干细胞(iPS细胞)的研究进展

通过转染特定的基因组合可以将已分化的体细胞重编程为多潜能干细胞,这种干细胞称为诱导性多潜能干细胞(induced pluripotent stem cells,iPS cells)。这是近年来干细胞研究领域最令人瞩目的一项新的干细胞制备技术。iPS细胞的出现不仅为体细胞重编程去分化机制的研究提供了新的模型,而且为疾病发生发展相关机制研究与特异的细胞治疗带来了新的希望。就当前获取iPS细胞的方法、影响iPS细胞转化率和多能性维持的一些因素及其研究进展进行综述。     

疾病特异诱导多能干细胞研究进展

通过病毒或非病毒转导体系,在小鼠和人的体细胞中人为表达几个与细胞多能性相关的转录因子,从而使细胞达到类似于胚胎干细胞（embryonic stem cells,ESCs）状态,是近年来新发展起来的体细胞重编程技术。这些被重编程的细胞称为诱导多能干细胞（induced pluripotent stem cells,iPS细胞）。这项技术为获得患者和疾病特异的多能干细胞提供了新的途径。患者和疾病特异的iPS细胞的获得,不仅在避免免疫排斥的宿主特异的细胞移植治疗上有广泛前景,并对了解疾病发生机理、药物筛选和毒性研究有着重要的意义。该文综述从iPS细胞技术的发明入手,着重讨论疾病iPS细胞的研究进展及其在应用于治疗时亟需解决的问题。     

The promise of human induced pluripotent stem cells for research and therapy

Induced pluripotent stem (iPS) cells are human somatic cells that have been reprogrammed to a pluripotent state. There are several hurdles to be overcome before iPS cells can be considered as a potential patient-specific cell therapy, and it will be crucial to characterize the developmental potential of human iPS cell lines. As a research tool, iPS-cell technology provides opportunities to study normal development and to understand reprogramming. iPS cells can have an immediate impact as models for human diseases, including cancer     

不同物种诱导性多潜能干细胞研究进展及应用

将特定的转录因子转入细胞并使其重编程后,获得与胚胎干细胞极其相似的多潜能性干细胞,称为诱导性多潜能干细胞(induced Pluripotent Stem Cells,iPS),它是由日本Yamanaka研究小组首次构建并命名。iPS细胞具有极强地自我更新和多项分化潜能,有发育和分化形成机体内几乎所有组织细胞类型的潜能,从而构成机体各种复杂的组织器官,且避免了在伦理、道德、宗教、法律和免疫排斥等诸多问题。随着iPS技术的不断发展,不同物种的iPS细胞相继产生,为细胞代替治疗、疾病模型的建立和药物筛选及再生医学等注入了新的活力。目前,iPS细胞的研究尚处于初级阶段,在临床应用上还存在诸多问题,本文将对近年来不同物种iPS细胞的产生、应用,及我们未来面临的问题和挑战进行综述。     

Induced pluripotent stem cells: a new technology to study human diseases

Induced pluripotent stem cells (iPS cells) are somatic cells that have been reprogrammed to a pluripotent state by the introduction of specific factors. They can be generated from cells of different origins such as fibroblasts, keratinocytes, hepatocytes and blood. iPS cells are similar to embryonic stem cells in several aspects such as morphology, expression of pluripotency markers and the capacity to develop teratomas; tumors containing cells of the three germ layers. As pluripotent stem cells they can be differentiated into several lineages including neuronal, cardiac and blood cells. Recently, several groups have successfully generated patient-specific iPS cells from donors suffering different disorders and differentiated them into the cell type affected by the disease. These new human cell-based models cannot only be used to study the dynamics of diseases but also as systems to screen new drugs. Moreover, iPS cells promise to be good candidates for regenerative medicine.     

Generation of Induced Pluripotent Stem Cell Lines from Tibetan Miniature Pig

Induced pluripotent stem cell (iPS) technology appears to be a general strategy to generate pluripotent stem cells from any given mammalian species. So far, iPS cells have been reported for mouse, human, rat, and monkey. These four species have also established embryonic stem cell (ESC) lines that serve as the gold standard for pluripotency comparisons. Attempts have been made to generate porcine ESC by various means without success. Here we report the successful generation of pluripotent stem cells from fibroblasts isolated from the Tibetan miniature pig using a modified iPS protocol. The resulting iPS cell lines more closely resemble human ESC than cells from other species, have normal karyotype, stain positive for alkaline phosphatase, express high levels of ESC-like markers (Nanog, Rex1, Lin28, and SSEA4), and can differentiate into teratomas composed of the three germ layers. Because porcine physiology closely resembles human, the iPS cells reported here provide an attractive model to study certain human diseases or assess therapeutic applications of iPS in a large animal model.     

诱导多能干细胞研究进展

人类诱导多能干细胞（induced pluripotent stem cells,iPS细胞）的建立被公认为目前最重要的科技进展之一。iPS细胞在动物疾病模型上的成功治疗,病患特异性iPS细胞的研究及iPS细胞的定向分化研究将有可能使人们避开治疗性克隆的伦理和技术障碍,给人类疾病的干细胞治疗带来光明的前景。本文从iPS细胞的诱导策略和方法,来源细胞及筛选、重编程机制的研究现状、应用前景以及研究中存在的问题等方面对其作一综述和讨论。     

诱导多能干细胞(iPS)的诱导培养与鉴定

通过外源转录调控因子的诱导,使成体细胞重编程为胚胎干细胞(ES细胞)样的多能细胞,这种细胞称为诱导多能干细胞(iPS细胞),这一方法被称为iPS技术。目前,iPS技术已先后在小鼠、人、猕猴、大鼠和猪中成功应用,建立了相应的iPS细胞系,并获得了iPS细胞嵌合小鼠和四倍体克隆小鼠。尽管iPS与ES细胞在形态和生长特性上有许多相同之处,但iPS细胞的建立需要较独特的诱导培养体系和鉴定方法。以下结合近年来iPS技术的发展和本实验室的相关研究,对iPS细胞的建立和培养体系的优化进行了深入探讨。     

Human-Induced Pluripotent Stem Cells: In Quest of Clinical Applications

In the field of regenerative medicine, the development of induced pluripotent stem (iPS) cells may represent a potential strategy to overcome the limitations of human embryonic stem cells (ESCs). iPS cells have the potential to mimic human disease, since they carry the genome of the donor. Hypothetically, with iPS cell technology it is possible to screen patients for a genetic cause of disease (genetic mutation), develop cell lines, reprogram them back to iPS cells, finally differentiate them into one or more cell types that develop the disease. Although the creation of multiple lineages with iPS cells can seem limitless, a number of challenges need to be addressed in order to effectively use these cell lines for disease modeling. These include the low efficiency of iPS cell generation without genetic alterations, the possibility of tumor formation in vivo, the random integration of retroviral-based delivery vectors into the genome, and unregulated growth of the remaining cells that are partially reprogrammed and refractory to differentiation. The establishment of protein or RNA-based reprogramming strategies will help generate human iPS cells without permanent genetic alterations. Finally, direct reprogramming strategies can provide rapid production of models of human ??diseases in a dish??, without first passing the cells through a pluripotent state, so avoiding the challenges of time-consumming and labor-intensive iPS cell line generation. This review will overview methods to develop iPS cells, current strategies for direct reprogramming, and main applications of iPS cells as human disease model, focusing on human cardiovascular diseases, with the aim to be a potential information resource for biomedical scientists and clinicians who exploit or intend to exploit iPS cell technology in a range of applications.     

iPS细胞的遗传安全性

自2006年Takahashi和Yamanaka首次成功地从小鼠成纤维细胞诱导得到诱导多能性干细胞(Induced pluripotent stem cells,iPS细胞)以来,iPS细胞由于其潜在的广阔应用前景而迅速成为干细胞研究领域的新热点;与此同时,iPS细胞的遗传安全性也越来越多地受到人们的关注。文章将对iPS细胞遗传安全性的研究进展进行综述,分析造成iPS细胞遗传不稳定的可能原因,希望可以促进对iPS细胞诱导条件的优化,获得遗传上较为安全的iPS细胞。     

iPS细胞的遗传安全性

自2006年Takahashi和Yamanaka首次成功地从小鼠成纤维细胞诱导得到诱导多能性干细胞(Induced pluripotent stem cells, iPS细胞)以来, iPS细胞由于其潜在的广阔应用前景而迅速成为干细胞研究领域的新热点; 与此同时, iPS细胞的遗传安全性也越来越多地受到人们的关注。文章将对iPS细胞遗传安全性的研究进展进行综述, 分析造成iPS细胞遗传不稳定的可能原因, 希望可以促进对iPS细胞诱导条件的优化, 获得遗传上较为安全的iPS细胞。     

综述: 诱导重编程过程中的表观遗传重塑

多能干细胞(pluripotent stem cell,PSC)是一类具有自我更新能力和多向分化潜能的细胞,具有广泛的临床应用前景．诱导性多功能干细胞(induced pluripotent stem cell,iPS cell)的获得,解决了传统方式中的细胞来源和伦理学等问题,从理论研究和应用上实现了体细胞重编程的重大突破,也为疾病发生机制研究、药物筛选、个性化药物选择、细胞治疗和再生医学等研究创造了难得的机会,从而开启了多能干细胞应用的新纪元．iPS过程中有很多问题尚未得到解决,尤其是诱导重编程的分子机制方面,这也是近年来干细胞领域研究的热点．其中如何实现表观遗传的重编程被认为是亟待解决的核心问题之一．本文结合我们的研究,主要介绍诱导重编程领域表观遗传修饰重塑机制的研究进展,并展望未来研究中大规模信息整合分析的重要性．     

哺乳动物DNA甲基化及其在体细胞诱导重编程中的作用

诱导多能干细胞(Induced pluripotent stem cell, iPS)技术提供了将终末分化的细胞逆转为多潜能干细胞的可能, 在干细胞基础理论研究和再生医学中具有重要意义。然而, 目前体细胞诱导重编程方法效率极低, 常发生不完全的重编程。研究表明, 在不完全重编程的细胞中存在体细胞的表观遗传记忆, 而DNA甲基化作为相对长期和稳定的表观遗传修饰, 是影响重编程效率和iPS细胞分化能力的重要因素之一。哺乳动物DNA甲基化是指胞嘧啶第五位碳原子上的甲基化修饰, 常发生于CpG位点。DNA甲基化能够调节体细胞特异基因和多能性基因的表达, 因此其在哺乳动物基因调控、胚胎发育和细胞重编程过程中发挥着重要作用。此外, 异常DNA甲基化可能导致iPS细胞基因印记的异常和X染色体的失活。文章重点围绕DNA甲基化的机制、分布特点、及其在体细胞诱导重编程中的作用进行了综述。     

A novel strategy to derive iPS cells from porcine fibroblasts

Induced pluripotent stem (iPS) cell technology demonstrates that somatic cells can be reprogrammed to a pluripotent state by over-expressing four reprogramming factors. This technology has created an interest in deriving iPS cells from domesticated animals such as pigs, sheep and cattle. Moloney murine leukemia retrovirus vectors have been widely used to generate and study mouse iPS cells. However, this retrovirus system infects only mouse and rat cells, which limits its use in establishing iPS cells from other mammals. In our study, we demonstrate a novel retrovirus strategy to efficiently generate porcine iPS cells from embryonic fibroblasts. We transfected four human reprogramming factors (Oct4, Sox2, Klf4 and Myc) into fibroblasts in one step by using a VSV-G envelope-coated pantropic retrovirus that was easily packaged by GP2-293 cells. We established six embryonic stem (ES)-like cell lines in human ES cell medium supplemented with bFGF. Colonies showed a similar morphology to human ES cells with a high nuclei-cytoplasm ratio and phase-bright flat colonies. Porcine iPS cells could form embryoid bodies in vitro and differentiate into the three germ layers in vivo by forming teratomas in immunodeficient mice.     

SNL fibroblast feeder layers support derivation and maintenance of human induced pluripotent stem cells

Induced pluripotent stem(iPS) cells can be derived from human somatic cells by cellular reprogramming.This technology provides a potential source of non-controversial therapeutic cells for tissue repair,drug discovery,and opportunities for studying the molecular basis of human disease.Normally,mouse embryonic fibroblasts(MEFs) are used as feeder layers in the initial derivation of iPS lines.The purpose of this study was to determine whether SNL fibroblasts can be used to support the growth of human iPS cell...